CTOs on the Move

Iomai Corporation

www.iomai.com

 
Iomai Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.iomai.com
  • 20 Firstfield Rd Ste 250
    Gaithersburg, MD USA 20878
  • Phone: 301.556.4500

Executives

Name Title Contact Details

Similar Companies

TissueVision

TissueVision Inc. (TVI) is a multi-disciplinary life sciences company offering 3D tissue imaging and analysis solutions for the research market. Our powerful Serial Two-Photon Plus (STP²) platform features stunning high-resolution multispectral datasets and analysis pipelines that create reliable 3D tissue models. The indexed histological sections produced during the STP² process can be further investigated with secondary analyses that run the gamut from standard histological stains to advanced spatial genomics. The final result is rich, multiplexed 3D models that deliver actionable and quantitative results. TVI provides project design, GLP-like documentation, including full protocol and report generation, and quality control review measures of all study-related materials. TVI is a solution provider to help answer research questions in a variety of therapeutic areas, including neuroscience, cancer, neurodegeneration, ophthalmology, and dermatology.

CepTor Corporation

CepTor Corporation is a Cockeysville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TissueTech

TissueTech, Inc is a Biotechnology company headquartered in Miami, FL. TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. TissueTech offers its portfolio of amniotic membrane and umbilical cord-based tissue and device products through its commercial entities: BioTissue, Inc: the industry leader in regenerative tissue therapies for ocular surface diseases and disorders. Amniox Medical: a leading technology provider to the musculoskeletal and wound care markets.

Bioporto

BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.

Vyripharm Enterprises

Vyripharm® is a disruptive biopharmaceutical innovator in personalized medicine. We are challenging the status quo by shifting medical paradigms through the integration of traditional and alternative medicines. Our purpose is to push the boundaries to drive innovation by turning groundbreaking science into cutting edge diagnostics and therapeutics.